Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.86 USD
-0.46 (-1.68%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $26.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
ALKS 26.86 -0.46(-1.68%)
Will ALKS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Here's Why Alkermes (ALKS) is a Strong Growth Stock
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
Other News for ALKS
Alkermes: Fairly Valued After Post-Earnings Bump
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
Alkermes PLC (ALKS) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth Amid ...
Strong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive Outlook
Alkermes price target raised by $1 at Baird, here's why